UCB's Global Corporate Website

This section is intended for media and financial analysts

Acquisition of own shares

Brussels (Belgium), 4 April 2019 – 20:00 (CEST) – regulated information

In application of article 207 of the Royal Decree executing the Companies Code, UCB SA/NV announces that on 28 March 2019, UCB SA/NV and 14 direct affiliates bought 39 327 and 82 132 UCB shares respectively (settlement date 1 April 2019), OTC from an affiliate, at a price of € 76.59 per share, in view of deliveries of shares to employees within the framework of the Long Term Incentive Program of the UCB Group. 

The highest independent bid price on Euronext Brussels on 28 March 2019 was € 77.34.

On 1 April 2019, after settlement of these transactions and the deliveries of these shares to employees, UCB SA/NV (taking into account the holdings of its affiliates) owned 5 879 678 UCB shares, which represent 3.02% of the total number of shares issued by the company (194 505 658).

An updated overview of the UCB SA/NV large shareholdings is available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Asset Download

Stay up-to-date on the latest news and information from UCB